Thrombosis and Haemostasis, Inhaltsverzeichnis Thromb Haemost 1997; 78(01): 548-552DOI: 10.1055/s-0038-1657586 The drug trials that have influenced our clinical practice in the treatment of thrombosis Schattauer GmbH Stuttgart How Have Trials of Thrombolytics Influenced Clinical Management of Patients with Acute Myocardial Infarction Victor J Marder University of Rochester School of Medicine and Dentistry, Rochester, NY, USA › Institutsangaben Artikel empfehlen Abstract als PDF herunterladen Artikel einzeln kaufen PDF (1126 kb) Referenzen References 1 Urokinase-Streptokinase Embolism Trial. Phase 2 Results. A cooperative Study. JAMA 1974; 229: 1606 2 Fletcher AP, Alkjaersig N, Smymiotis FE, Sherry S. The treatment of patients suffering from early MI with massive and prolonged SK therapy. Trans Assoc Am Phys 1958; 71: 287 3 Rentrop KP, Blanke H, Karsch KR. et al. AMI: Intracoronary application of nitroglycerin and SK. Clin Cardiol 1979; 01: 354 4 DeWood MA, Spores J, Notske R. et al. Prevalence of total coronary occlusion during the early hours of transmural MI. N Engl J Med 1980; 303: 897 1980 5 European Cooperative Study Group for SK Treatment in AMI: AMI. N Engl J Med 1979; 301: 797 6 Braunwald E. Treatment of the patient after myocardial infarction. The last decade and the next. N Engl J Med 1980; 302: 290-293 7 Stampfer MJ, Goldhaber SZ, Yusuf S, Peto R, Hennekens CH. Effects of intravenous streptokinase on acute myocardial infarction: pooled results from randomized trials. N Engl J Med 1982; 307: 1180-1182 8 Yusuf S, Collins R, Peto R. et al. Intravenous and intracoronary fibrinolytic therapy in acute myocardial infarction: overview of results on mortality, reinfarction and side-effects from 33 randomized controlled trials. Eur Heart J 1985; 06: 556-585 9 Boucek RJ, Murphy Jr WP. Segmental perfusion of the coronary arteries with fibrinolysin in man following MI. Am J Cardiol 1960; 06: 525 10 Marder VJ, Francis CW. Thrombolytic therapy for acute transmural myocardial infarction: intracoronaiy versus intravenous. Am J Med 1984; 77: 921-928 11 Kennedy JW, Ritchie JL, Davis KB, Stadius ML, Maynard C, Fritz JK. The Western Washington randomized trial of intracoronary streptokinase in acute myocardial infarction: a 12-month follow-up report. N Engl J Med 1985; 312: 1073-1078 12 The TIMI Study Group. The thrombolysis in myocardial infarction (TIMI) trial: Phase I findings. N Engl J Med 1985; 312: 932-936 13 Reiman AS. Intravenous thrombolysis in acute myocardial infarction. A progress report. N Engl J Med 1985; 312: 915-916 14 The TIMI Study Group. Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) Phase II trial. N Engl J Med 1989; 320: 618-627 15 Verstraete M, Bernard R, Bory M. et al. Randomised trial of intravenous recombinant tissue-type plasminogen activator versus intravenous streptokinase in acute myocardial infarction: report from the European Cooperative Study Group for Recombinant Tissue-type Plasminogen Activator. Lancet 1985; 01: 842-847 16 Gruppo Italiano per lo Studio della Streptochinasi nell’Infarto Miocardica (GISSI): Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986; 01: 397 17 Gruppo Italiano per lo Studio della Streptochinasi nell’Infarto Miocardico (GISSI). Long-term effects of intravenous thrombolysis in acute myocardial infarction: final report of the GISSI study. Lancet 1987; 02: 871 18 ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; 02: 349 19 Wilcox RG, von der LippeG, Olsson CG, Jensen G, Skene AM, Hampton JR. for the ASSET (Anglo-Scandinavian Study of Early Thrombolysis) Study Group Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction: Anglo-Scandinavian Study of Early Thrombolysis (ASSET). Lancet 1988; 02: 525 20 Wilcox RG, von der Lippe, Olsson CG, Jensen G, Skene AM, Hampton JR. For the Angelo-Scandinavian Study of Early Thrombolysis. Effects of alteplase in acute myocardial infarction: 6-month results from the ASSET study: Anglo-Scandinavian Study of Early Thrombolysis. Lancet 1990; 335: 1175 21 AIMS Trial Study Group. Effect of intravenous APSAC on mortality after acute myocardial infarction: preliminary report of a placebo-controlled clinical trial: AIMS Trial study group. Lancet 1988; 01: 545 22 AIMS Trial Study Group. Long-term effects of intravenous anistreplase in acute myocardial infarction: final report of the AIMS study. AIMS Trial study group. Lancet 1990; 335: 427 23 Fibrinolytic Therapy Trialists’ (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1,000 patients. Lancet 1994; 343: 311 24 Rovelli F, Tognoni G. The health service as a laboratory. Lancet 1996; 348: 167-175 25 Ketley D, Woods KL. Impact of clinical trials on clinical practice: example of thrombolysis for acute myocardial infarction. Lancet 1993; 342: 891-894 26 Immonen-Räihä P, Arstila M, Tuomilehto J, Haikio M, Mononen A, Vuorenmaa T, Torppa J, Parvinen I. 21 year trends in incidence of myocardial infarction and mortality from coronary disease in middle-age. Eur Heart J 1996; 17: 1495-1502 27 McGovern PG, Pankow JS, Shahar E, Doliszny KM, Folson AR, Blackburn H, Leupker RV. for the Minnesota Heart Survey Investigators. N Engl J Med 1996; 334: 884-890 28 Gray D, Keating NA, Murdock J, Skene AM, Hampton JR. Impact of hospital thrombolysis policy on out-of-hospital response to suspected myocardial infarction. Lancet 1993; 341: 654-657 29 Gruppo Italiano per lo Studio Della SopravvivenzaNeirinfarto Miocardico. GISSI-2: A factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Lancet 1990; 336: 65-71 30 The International Study Group. In-hospital mortality and clinical course of 20,891 patients with suspected acute myocardial infarction randomised between alteplase and streptokinase with or without heparin. Lancet 1990; 336: 71-75 31 ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. ISIS-3: A randomised comparison of streptokinase vs. tissue plasminogen activator vs. anistreplase and of aspirin plus heparin vs. aspirin alone among 41,299 cases of suspected acute myocardial infarction. Lancet 1992; 339: 753-770 32 The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993; 329: 673-682 33 Califf RM, White HD, Van de WerfF, Sadowski Z, Armstrong PW, Vahanian A, Simoons ML, Simes RJ, Lee KL, Topol EJ. for the GUSTO-I Investigators One-year results from the global utilization of streptokinase and t-PA for occluded coronary arteries (GUSTO-I) Trial. Circulation 1996; 94: 1233-1238 34 Ridker PM, O’Donnell C, Marder VJ, Hennekens CH. Large-scale trials of thrombolytic therapy for acute myocardial infarction: GISSI-2, ISIS-3, and GUSTO-1. Ann Intern Med 1993; 119: 530-532 35 Lee KL, Califf RM, Simes J, Van de WerfF, Topol EJ. for the GUSTO Investigators Holding GUSTO up to the light. Ann Intern Med 1994; 120: 876-881 36 Ridker PM, O’Donnell CJ, Marder VJ, Hennekens CH. A response to “Holding GUSTO up to the light”. Ann Intern Med 1994; 120: 882-885 37 Farkouh ME, Lange JK, Sackett DL. Thrombolytic agents: The science of the art of choosing the better treatment. Ann Intern Med 1994; 120: 886-888 38 Pashos CL, Normand S-LT, Garfinkle JB, Newhouse JP, Epstein AM, McNeil BJ. Trends in the use of drug therapies in patients with acute myocardial infarction: 1988 to 1992. J Am Coll Cardiol 1994; 23: 1023-1030 39 Raymond WD, Shahar E, McGovern PG, Sides TL, Luepker RV. Trends in coronary thrombolytic therapy for acute myocardial infarction (The Minnesota Heart Survey Registry, 1990 to 1993). Am J Cardiol 1996; 78: 271-277 40 European Secondary Prevention Study Group. Translation of clinical trials into practice: a European population-based study of the use of thrombolysis for acute myocardial infarction. Lancet 1996; 347: 1203-1207 41 Ketley D, Woods KD. for the European Secondary Prevention Study Group Selection factors for the use of thrombolytic treatment in acute myocardial infarction: a population based study of current practice in the United Kingdom. Br Heart J 1995; 74: 224-228 42 Guidelines for the early management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Subcommittee to Develop Guidelines for the Early Management of Patients with Acute Myocardial Infarction). J Am Coll Cardiol 1990; 16: 249-292 43 Sherry S, Marder VJ. Mistaken guidelines for thrombolytic therapy of acute myocardial infarction in the elderly. J Am Coll Cardiol 1991; 17: 1237-1238 44 Gurwitz JH, Gore JM, Goldberg RJ, Rubison M, Chandra N, Rogers WJ. for the participants in the National Registry of Myocardial Infarction Recent age-related trends in the use of thrombolytic therapy in patients who have had acute myocardial infarction. Ann Intern Med 1996; 124: 283-291 45 Maynard C, Althouse R, Cerqueira M, Olsufka M, Kennedy JW. Utilization of thrombolytic therapy in eligible women with acute myocardial infarction. Am J Cardiol 1991; 68: 529-539 46 Eysmann SB, Douglas PS. Reperfusion and revascularization strategies for coronary artery disease in women. JAMA 1991; 268: 1903-1907 47 O’Callaghan PA, Comerford DM, Graham IM, Higgins I, Daly LE, Robinson K, McLoughlin M, Kilcoyne D, Hickey N, Walsh MJ. National perspective of acute coronary care in the Republic of Ireland. Br Heart J 1995; 73: 576-580 48 Rule S, Brooksby P, Sanderson J. Use of thrombolysis for acute myocardial infarction by general practitioners. Postgrad Med J 1993; 69 V.J.Marder 13..1997; (619) 784-7353
